← Back to patent-cliff list
Bucillamine ((Intravenous)
Tier C — Watch / tradeBucillamine ((Intravenous)
Revive Therapeutics Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Brand：Rimatil
Indications (approved)：再灌注损伤
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bucillamine ((Intravenous)?
Approved indications include: 再灌注损伤.
When does the Bucillamine ((Intravenous) patent expire?
No public expiry year is available for Bucillamine ((Intravenous) yet; this page updates once verified.
How do I get a quote for Bucillamine ((Intravenous) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30